Hop­ing to take drug R&D in­to the cloud, In­sight­ful Sci­ence snaps up da­ta man­age­ment out­fit Dot­mat­ics

As com­pa­nies quick­ly move to­ward more in­no­v­a­tive meth­ods of R&D to in­crease sci­en­tists’ ef­fi­cien­cy, two soft­ware com­pa­nies an­nounced that they will join forces Mon­day in the lat­est string of cloud-based deals.

UK soft­ware provider In­sight­ful Sci­ence will ac­quire Dot­mat­ics, a cloud-based sci­en­tif­ic R&D da­ta man­age­ment plat­form based in San Diego. The com­bi­na­tion is in­tend­ed to im­prove lab­o­ra­to­ry ef­fi­cien­cy and fa­cil­i­tate quick­er da­ta ac­cess, analy­sis and ex­change be­tween sci­en­tists, the com­pa­nies said.

Thomas Swal­la

Fi­nan­cial terms were not an­nounced in the press re­lease Mon­day, but Bloomberg re­ports that the deal is val­ued at up to $690 mil­lion. The move could gen­er­ate over $100 mil­lion in rev­enue, the re­lease said, and will im­prove lab ef­fi­cien­cy for more than 1 mil­lion sci­en­tists.

“This an­nounce­ment sig­nals a sig­nif­i­cant trans­for­ma­tion in the fu­ture of soft­ware and da­ta man­age­ment in re­search labs,” In­sight­ful CEO Thomas Swal­la said in a state­ment. “To­geth­er our com­ple­men­tary busi­ness­es cre­ate an end-to-end cloud-first sci­en­tif­ic re­search plat­form that stands apart in our col­lec­tive abil­i­ty to sup­port da­ta-dri­ven re­search.”

Dot­mat­ics was found­ed in 2005 by two sci­en­tists from Mer­ck and has since grown to a team of over 260 sci­en­tists. It’s a sci­en­tif­ic in­for­mat­ics soft­ware and ser­vices com­pa­ny that is fo­cused on the au­toma­tion of lab­o­ra­to­ry work­flow.

Stephen Gal­lagher

“This com­bi­na­tion al­lows us to ex­pand in­vest­ments in our Dot­mat­ics plat­form and strength­en our brand as a lead­ing en­ter­prise in­for­mat­ics so­lu­tion provider,” Dot­mat­ics CEO and co-founder Stephen Gal­lagher said in a state­ment.

The ac­qui­si­tion fur­ther high­lights the in­dus­try’s in­crease in cloud-based soft­ware deals. In Sep­tem­ber, Flag­ship in­vest­ed $100 mil­lion in cloud com­put­ing. Ear­li­er in March, the com­pa­ny re­ceived a $110 mil­lion in­vest­ment from Koch Dis­rup­tive Tech­nol­o­gy.

In late Feb­ru­ary, New York-based Schrödinger fi­nal­ized a deal with Google Cloud to in­crease the speed and ca­pac­i­ty of its plat­form for drug dis­cov­ery, a move the com­pa­ny said tripled its pre­vi­ous ca­pac­i­ty.

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Tom Barnes, Orna Therapeutics CEO

UP­DAT­ED: 'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Merck went in deep on its collaboration with Moderna on new mRNA programs, and dropped them all over time, including their RSV partnership. But after writing off what turned out as one of the most successful infectious disease players in the business, Merck is coming in this morning with a new preclinical alliance — this time embracing a biotech that hopes to eventually outdo the famously successful mRNA in a new run at vaccines and therapeutics.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has landed a new first from UNICEF the first-ever contract for malaria vaccines, worth up to $170 million for 18 million vaccine doses distributed over the next three years.

The vaccine, known as Mosquirix or RTS,S, won WHO’s backing last October after a controversial start, but UNICEF said these doses will potentially save thousands of lives every year.

“We hope this is just the beginning,” Etleva Kadilli, director of UNICEF’s supply division, said. “Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”

Kate Haviland, Blueprint Medicines CEO

Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

Blueprint Medicines announced this morning that the second part of its study on Ayvakit in non-advanced systemic mastocytosis (SM) — a rare disease in which a type of white blood cells known as mast cells builds up — met all endpoints, but the biopharma left key questions unanswered.

In 212 patients, with 141 in the treatment arm and 71 in the control arm, patients who got Ayvakit saw an average 15.6-point decrease in their symptom scores compared to a 9.2-point decrease in the placebo arm at 24 weeks. In an extension study, those on Ayvakit saw their symptom scores drop by 20.2 points by week 48.

Atomwise CEO and co-founder Abraham Heifets (left) and co-founder Izhar Wallach

A cou­ple bil­lion for Ex­sci­en­tia was on­ly part of Sanofi's AI am­bi­tions, as the Big Phar­ma adds Atom­wise to the ta­ble

Sanofi made clear its AI ambitions were real at the beginning of this year when the Big Pharma took its drug discovery collaboration with Exscientia to the next level, inking a pact that could birth 15 drugs and deliver $5.3 billion to the UK partner.

Seven months later, the AI blueprint is far from over at the French Big Pharma, as another of the much-hyped drug discovery startups is coming to the table in a five-drug deal. Sanofi will pay Atomwise $20 million to kick off the hunt for up to five targets, which are aimed at leading to the creation of new small molecules. Another $1 billion is on the line — as are royalties — and the companies kept mum on the specific diseases or broader therapeutic areas of interest.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is officially giving up on its oral SERD.

The French drugmaker put out word Wednesday morning that it will discontinue the global development program of amcenestrant, the selective estrogen receptor degrader once billed as a top late-stage prospect. Having already failed a Phase II monotherapy test earlier this year, a combo with the drug also missed the bar in a second trial for breast cancer, triggering the decision to drop the whole program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Paul Perreault, CSL Behring CEO

CSL CEO Paul Per­reault de­ter­mined to grow plas­ma col­lec­tion af­ter full-year sales dip

As the ink dries on CSL’s $11.7 billion Vifor buyout, the company posted a dip in profits, due in part to a drop in plasma donations amid the pandemic.

However, CEO Paul Perreault assured investors and analysts on the full-year call that the team has left “no stone unturned” when assessing options to grow plasma volumes. The chief executive also spelled out positive results for the company’s monoclonal antibody garadacimab in hereditary angioedema (HAE), though he isn’t revealing the exact numbers just yet.